Vanda Is 1-1 In Fights With FDA As Court Grants Its FOIA Request For Review Documents
Executive Summary
Court finds the agency and public would not be harmed if FDA turns over its clinical and statistical reviews of Vanda’s application for Hetlioz jet lag indication. Battles continue over FDA approval of generic Hetlioz and agency’s proposal to refuse the jet lag sNDA.